美股异动 | 心血管药企Braveheart Bio(BRVE.US)登陆美股市场 开盘后股价涨超75%

智通财经
Aug 07
【美股异动 | 心血管药企Braveheart Bio(BRVE.US)登陆美股市场 开盘后股价涨超75%】智通财经APP获悉,周四,心血管药企Braveheart Bio(BRVE.US)登陆美股市场,截至发稿,该股涨超75%,报31.405美元。IPO价格为18美元。Braveheart Bio成立于2024年,是一家处于临床后期的生物制药公司,专注于开发肥厚型心肌病(HCM)及其他严重心血管疾病的创新疗法。公司的核心候选药物BHB-1893(亦称HRS-1893)是一种口服小分子心肌肌球蛋白抑制剂,通过特异性抑制心肌肌球蛋白ATP酶活性,使心肌收缩性能正常化,减少左心室肥厚并改善舒张期顺应性。该药物于2025年9月从中国江苏恒瑞医药获得全球(除大中华区外)独家许可授权。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10